OBJECTIVE: To evaluate the long-term safety and efficacy of memantine use as treatment of HIV-associated cognitive impairment. BACKGROUND: The results of a 20-week, randomized, double-blind, placebo-controlled trial of memantine in HIV-infected participants with cognitive impairment (ACTG 301) were previously reported. We report the results of the up-to-60-week open-label phase following the double-blind phase. METHOD: Participants received open-label memantine and were escalated to a 40 mg/day dose or their maximum tolerated dose in the double- blind phase. Adverse experiences were used to evaluate safety, and changes in the mean of eight neuropsychological test scores (NPZ-8) were used to evaluate efficacy. RESULTS:Ninety-nine participants entered the initial 12-week open-label phase and 45 in the additional 48-week extension. Twenty-seven participants reported severe adverse experiences. During the initial 12-week open-label phase, participants randomized to memantine in the double-blind phase had a statistically significant higher improvement in NPZ-8 compared to those randomized to placebo in the double-blind phase. No statistically significant NPZ-8 changes were detected during the 48-week extension. CONCLUSION: Long-term use of memantine appears safe and tolerable. Future randomized studies with longer follow-up are necessary to establish efficacy of memantine for the treatment of HIV-associated cognitive impairment.
RCT Entities:
OBJECTIVE: To evaluate the long-term safety and efficacy of memantine use as treatment of HIV-associated cognitive impairment. BACKGROUND: The results of a 20-week, randomized, double-blind, placebo-controlled trial of memantine in HIV-infectedparticipants with cognitive impairment (ACTG 301) were previously reported. We report the results of the up-to-60-week open-label phase following the double-blind phase. METHOD:Participants received open-label memantine and were escalated to a 40 mg/day dose or their maximum tolerated dose in the double- blind phase. Adverse experiences were used to evaluate safety, and changes in the mean of eight neuropsychological test scores (NPZ-8) were used to evaluate efficacy. RESULTS: Ninety-nine participants entered the initial 12-week open-label phase and 45 in the additional 48-week extension. Twenty-seven participants reported severe adverse experiences. During the initial 12-week open-label phase, participants randomized to memantine in the double-blind phase had a statistically significant higher improvement in NPZ-8 compared to those randomized to placebo in the double-blind phase. No statistically significant NPZ-8 changes were detected during the 48-week extension. CONCLUSION: Long-term use of memantine appears safe and tolerable. Future randomized studies with longer follow-up are necessary to establish efficacy of memantine for the treatment of HIV-associated cognitive impairment.
Authors: Jutta K Neuenburg; Hans R Brodt; Brian G Herndier; Markus Bickel; Peter Bacchetti; Richard W Price; Robert M Grant; Wolfgang Schlote Journal: J Acquir Immune Defic Syndr Date: 2002-10-01 Impact factor: 3.731
Authors: Barry Reisberg; Rachelle Doody; Albrecht Stöffler; Frederick Schmitt; Steven Ferris; Hans Jörg Möbius Journal: N Engl J Med Date: 2003-04-03 Impact factor: 91.245
Authors: Ned Sacktor; Michael P McDermott; Karen Marder; Giovanni Schifitto; Ola A Selnes; Justin C McArthur; Yaakov Stern; Steve Albert; Donna Palumbo; Karl Kieburtz; Joy A De Marcaida; Bruce Cohen; Leon Epstein Journal: J Neurovirol Date: 2002-04 Impact factor: 2.643
Authors: Pierre N Tariot; Martin R Farlow; George T Grossberg; Stephen M Graham; Scott McDonald; Ivan Gergel Journal: JAMA Date: 2004-01-21 Impact factor: 56.272
Authors: Sunita Gupta; Alecia G Knight; Shruti Gupta; Pamela E Knapp; Kurt F Hauser; Jeffrey N Keller; Annadora J Bruce-Keller Journal: Neurosci Lett Date: 2010-09-19 Impact factor: 3.046
Authors: Daniel F Marker; Marie-Ève Tremblay; Jenna M Puccini; Justin Barbieri; Mary A Gantz Marker; Colin J Loweth; E Chris Muly; Shao-Ming Lu; Val S Goodfellow; Stephen Dewhurst; Harris A Gelbard Journal: J Neurosci Date: 2013-06-12 Impact factor: 6.167